Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE

(ABBV)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

AbbVie : FDA moves the goal line on AbbVie`s endometriosis drug elagolix

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/11/2018 | 05:43am EDT

The FDA is pushing back the PDUFA date for AbbVie and Neurocrine`s drug for endometriosis-linked pain by three months, saying it needs more time to review the results of liver function tests. The agency is now expected to make a decision on the candidate in the third quarter this year.

The pair teamed up on elagolix in 2010, back when AbbVie was still part of Abbott. The pharma company took over development, forking over $75 million up front, with an additional $500 million in milestone payments on the line. The treatment nabbed a priority review designation at the end of 2017, setting it up for a Q2 approval.

The NDA for elagolix is based on what AbbVie calls the largest prospective randomized clinical trials that have been conducted for endometriosis, a disease where tissue that normally grows inside the uterus begins to grow outside that organ. About 1,700 women with moderate to severe endometriosis were enrolled in two studies, which reported topline results in February 2016. The drug is also being evaluated in the treatment of uterine fibroids.

"We are pleased with the outcomes of the pivotal trials thus far. AbbVie will continue to pursue Elagolix as a potential new treatment for the disease`s most common symptoms, including pain related to menstruation and chronic pelvic pain throughout the menstrual cycle," said Michael Severino, chief scientific officer at AbbVie, at the time.

Trial data showed that elagolix was well-tolerated and significantly reduced the three types of endometriosis-associated pain: daily menstrual pelvic pain, non-menstrual pelvic pain and painful intercourse.

"Based on our review of the data, we remain confident in our New Drug Application for elagolix in the treatment of endometriosis-associated pain," Severino said. "Elagolix has the potential to be an important new treatment option for women suffering from endometriosis and we are committed to working with the FDA to bring this therapy to patients."

(c) 2018 Arab Finance Brokerage Company All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBVIE
03/22ABBVIE : British Columbia PharmaCare Lists AbbVie's Hepatitis C Treatment MAVIRE..
AQ
03/21ABBVIE : Donates $40 Million to Rebuild North Chicago Middle School
PU
03/20ABBVIE : ABBV) Announces Partial Clinical Hold on VENCLEXTA/VENCLYXTO Trials
AQ
03/19FDA Puts Partial Hold on AbbVie's Venetoclax Clinical Trials for Multiple Mye..
DJ
03/19ABBVIE : Provides Update on VENCLEXTA®/VENCLYXTO® (venetoclax) Multiple Myeloma ..
PR
03/11PRINCIPIA BIOPHARMA : AbbVie End Oral Immunoproteasome Collaboration
DJ
03/07Genentech Submits Application for Venclexta Plus Gazyva for Chronic Lymphocyt..
DJ
03/07ABBVIE : Announces Multiple Milestones for Phase 3 CLL14 Venetoclax Study of Fix..
PU
03/04ABBVIE : Receives CHMP Positive Opinion for Risankizumab for the Treatment of Mo..
AQ
03/04ABBVIE : to Present at the Barclays Global Healthcare Conference
AQ
More news
Financials ($)
Sales 2019 32 863 M
EBIT 2019 15 286 M
Net income 2019 10 540 M
Debt 2019 31 514 M
Yield 2019 5,34%
P/E ratio 2019 10,97
P/E ratio 2020 10,02
EV / Sales 2019 4,54x
EV / Sales 2020 4,16x
Capitalization 118 B
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Average target price 92,2 $
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman & President
Azita Saleki-Gerhardt Senior Vice President-Operations
Robert A. Michael Chief Financial Officer & Senior Vice President
Carlos Alban Vice Chairman & Chief Commercial Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE-13.48%117 653
WUXI APPTEC CO LTD29.40%16 133
MERCK KGAA9.67%14 742
KYOWA HAKKO KIRIN CO LTD14.50%11 469
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD25.41%9 781
JAZZ PHARMACEUTICALS PLC9.74%7 761